Cargando…
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells
INTRODUCTION: Breast cancer is a devastating disease that results in approximately 40,000 deaths each year in the USA. Current drug screening and chemopreventatitive methods are suboptimal, due in part to the poor specificity of compounds for cancer cells. Poly (ADP-ribose) polymerase 1 (PARP1) inhi...
Autores principales: | Vazquez-Ortiz, Guelaguetza, Chisholm, Cristine, Xu, Xiaoling, Lahusen, Tyler J, Li, Cuiling, Sakamuru, Srilatha, Huang, Ruili, Thomas, Craig J, Xia, Menghang, Deng, Chuxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229979/ https://www.ncbi.nlm.nih.gov/pubmed/24962108 http://dx.doi.org/10.1186/bcr3682 |
Ejemplares similares
-
Lestaurtinib induces DNA damage that is related to estrogen receptor activation
por: Ooka, Masato, et al.
Publicado: (2022) -
Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways
por: Sakamuru, Srilatha, et al.
Publicado: (2022) -
Identification of repurposed small molecule drugs for chordoma therapy
por: Xia, Menghang, et al.
Publicado: (2013) -
Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.
por: Nagao, M, et al.
Publicado: (1991) -
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
por: De Soto, Joseph A., et al.
Publicado: (2006)